Group 1 - The innovative drug sector is experiencing significant activity, with multiple stocks, including Nanjing New Pharmaceutical and Qizheng Tibetan Medicine, hitting the daily limit up [1] - The focus of the market is on the major collaboration between Shijiazhuang Pharmaceutical Group and US biopharmaceutical company Madrigal Pharmaceuticals, involving the global rights transfer of the oral GLP-1 receptor agonist SYH2086 [1] - Shijiazhuang Pharmaceutical Group will receive a total transaction value of up to $2.075 billion, including an upfront payment of $120 million and potential milestone payments of up to $1.955 billion [1] Group 2 - The overall performance of pharmaceutical stocks is strong, with several stocks, including Nanjing New Pharmaceutical and Qizheng Tibetan Medicine, reaching the daily limit up [1] - In terms of market dynamics, the pharmaceutical and biological sector has a notable presence, with 7 out of 35 stocks hitting the daily limit up, indicating strong investor interest [2] - The innovative drug-related stocks are favored by market funds, with significant net inflows observed in the telecommunications equipment sector, amounting to 2.432 billion yuan [2]